Author

Karen Sims

Observed names: K Sims, K. D. Sims, K. Sims, K.D. Sims, Karen D Sims, Karen D. Sims

Observed institutions: Children's Hospital of Philadelphia, Bristol-Myers Squibb (Germany), Hospital of the University of Pennsylvania, Bristol-Myers Squibb (United States), Bristol-Myers Squibb (France), Bristol-Myers Squibb (United Kingdom), University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania

ORCID: 0000-0002-4824-494X

Observed ORCID: 0000-0002-4824-494X

OpenAlex ID: A5017942355

Efficacy of an Interferon- and Ribavirin-Free Regimen of Daclatasvir, Asunaprevir, and BMS-791325 in Treatment-Naive Patients With HCV Genotype 1 Infection

2013 · Gregory T. Everson, Karen D. Sims, et al. · Gastroenterology · 201

PDF

Expression Patterns and Regulation of Glutamate Transporters in the Developing and Adult Nervous System

1999 · Karen D. Sims, Michael B. Robinson · Critical Reviews in Neurobiology · 162

Platelet-derived Growth Factor Rapidly Increases Activity and Cell Surface Expression of the EAAC1 Subtype of Glutamate Transporter through Activation of Phosphatidylinositol 3-Kinase

2000 · Karen D. Sims, Dean J. Straff, et al. · Journal of Biological Chemistry · 130

PDF

Epstein-Barr Virus Nuclear Antigen 3C Augments Mdm2-Mediated p53 Ubiquitination and Degradation by Deubiquitinating Mdm2

2009 · Abhik Saha, Masanao Murakami, et al. · Journal of Virology · 114

Risk factors for nontuberculous mycobacterial infections in solid organ transplant recipients: a case–control study

2013 · S.A. Longworth, C. Vinnard, et al. · Transplant Infectious Disease · 89

A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection

2015 · Tarek Hassanein, Karen D. Sims, et al. · Journal of Hepatology · 53

Organic Anion Transporting Polypeptide‐Mediated Transport of, and Inhibition by, Asunaprevir, an Inhibitor of Hepatitis C Virus NS3 Protease

2014 · T Eley, Y‐H Han, et al. · Clinical Pharmacology & Therapeutics · 48

CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects

2016 · Li Zhu, Roger J. Brüggemann, et al. · The Journal of Clinical Pharmacology · 37

1423 Interim Analysis of an Interferon (ifn)- and Ribavirin (rbv)-free Regimen of Daclatasvir (dcv), Asunaprevir (asv), and Bms-791325 in Treatment-naive, Hepatitis C Virus Genotype 1-infected Patients

2013 · G.T. Everson, K.D. Sims, et al. · Journal of Hepatology · 37

PDF

NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection

2015 · Nannan Zhou, Dennis Hernandez, et al. · The Journal of Infectious Diseases · 35

PDF

Randomized, Placebo-Controlled, Single-Ascending-Dose Study of BMS-791325, a Hepatitis C Virus (HCV) NS5B Polymerase Inhibitor, in HCV Genotype 1 Infection

2014 · Karen D. Sims, Julie Lemm, et al. · Antimicrobial Agents and Chemotherapy · 32

Risk factors and clinical outcomes of cytomegalovirus disease occurring more than one year post solid organ transplantation

2012 · D. Blyth, I. Lee, et al. · Transplant Infectious Disease · 32

Common Infections in the Lung Transplant Recipient

2011 · Karen D. Sims, Emily A. Blumberg · Clinics in Chest Medicine · 31

Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB‐506 from Phase 1 studies in healthy subjects and those with hepatitis B

2022 · Man‐Fung Yuen, Elina Berliba, et al. · Hepatology Communications · 27

Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1‐infected treatment‐naive patients

2015 · Gregory T. Everson, Karen D. Sims, et al. · Liver International · 27

Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects

2017 · Tushar Garimella, Xiaolu Tao, et al. · Drugs in R&D · 24

PDF

Group B streptococcal toxic shock syndrome in an asplenic patient: case report and literature review

2006 · K. D. Sims, T. D. Barton · European Journal of Clinical Microbiology & Infectious Diseases · 23

Effect of Single vs Bilateral Lung Transplantation on Plasma Surfactant Protein D Levels in Idiopathic Pulmonary Fibrosis

2011 · Michael W. Sims, Michael F. Beers, et al. · CHEST Journal · 18

PDF

Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection

2020 · Rmf Yuen, E Berliba, et al. · 14

A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents

2014 · Heather Sevinsky, Xiaolu Tao, et al. · Antiviral Therapy · 13

P1163 All-oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-naive Patients With Chronic Hcv Genotype 4 Infection

2014 · T. Hassanein, K. Sims, et al. · Journal of Hepatology · 12

Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells

2022 · Sharie C Ganchua, Bhavna Paratala, et al. · Journal of Hepatology · 11

Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects

2022 · Man-Fung Yuen, Elina Berliba, et al. · Journal of Hepatology · 10

451 Evaluation of Pharmacokinetic Drug–drug Interaction (ddi) Between Bms-791325, an Ns5b Non-nucleotide Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in Hcv Genotype 1-infected Patients

2013 · X. Wang, W. Li, et al. · Journal of Hepatology · 9

Preliminary safety and antiviral activity of AB-729 combination treatment with pegylated interferon alfa-2a in virally suppressed, HBeAg-negative subjects with chronic HBV infection

2023 · Man-Fung Yuen, Jeong Heo, et al. · Journal of Hepatology · 8

Works count: 53

Citation count: 1,256

H-index: 18

I10-index: 23